

## Product Data Sheet

---

Product Name: Udenafil

Cat. No.: GC13287

### Chemical Properties

Cas. No. 268203-93-6

Chemical Name 3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-propoxybenzenesulfonamide

SMILES CCCC(C(N=C(N1)C2=C(OCCC)C=CC(S(NCCC3CCCN3C)(=O)=O)=C2)=C4C1=O)=N  
N4C

Formula C<sub>25</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub>S M.Wt 516.66

Solubility DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2) (1:4): 0.20 mg/ml, Ethanol: 1 mg/ml Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.


**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

### Structure



### Background

Udenafil (DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction. Target: PDE5. Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction [1]. After 12 weeks of treatment, the patients treated with udenafil showed significantly greater change from baseline in the IIEF-EF domain score compared with placebo (placebo, 0.20; 100-mg udenafil, 7.52; and 200-mg udenafil, 9.93, respectively) ( $P < 0.0001$ ). Udenafil significantly enhanced the rates of successful penetration (SEP Q2) and maintenance of erection (SEP Q3) ( $P < 0.0001$ ) [2].

### References:

- [1]. Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. *BJU Int*, 2011. 107(12): p. 1943-7.
- [2]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53.

***Caution: Product has not been fully validated for medical applications. For research use only.***

***Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: [tech@glpbio.com](mailto:tech@glpbio.com)***

***Address: 10292 Central Ave. #205, Montclair, CA, USA***